Roughly a dozen tumor types trace back to inherited DNA mismatch repair defects, spanning the colon, endometrium, ovaries, stomach, small bowel, urinary tract, brain, pancreas, prostate, and sebaceous skin. Colorectal cancer leads the list, often appearing before age 50 in the proximal (right-sided) colon, while endometrial cancer is the most common extracolonic tumor in women and frequently the first sign that prompts genetic testing. Carrying one of these germline mutations (changes present in every cell from birth, not just the tumor) roughly doubles or triples a person’s lifetime risk across several organ systems compared with the general population.
Below, every Lynch-associated cancer gets its own section, paired with lifetime risk ranges by gene so you can move from vague worry to a clear, personalized picture of what to watch for.
The Genetic Basis of Lynch Syndrome and Why Cancer Risk Varies
Five genes drive Lynch syndrome: MLH1, MSH2, MSH6, PMS2, and EPCAM. The first four build the mismatch repair (MMR) machinery, a team of proteins that corrects small spelling errors that happen every time a cell copies its DNA. EPCAM sits next to MSH2 and, when deleted, silences MSH2 from a distance, producing the same downstream effect as an MSH2 mutation. Because every cell in the body carries the defective copy from conception, a tumor only needs to lose its one working copy (a “second hit”) before DNA errors start piling up in critical growth-control genes.
Inheritance follows an autosomal dominant pattern, meaning a single mutated copy from either parent is enough to raise risk. Each child of a carrier has a 50% chance of inheriting the variant. Lynch does not skip generations the way some recessive conditions can; an unaffected parent simply did not pass the mutation on, which is why a family tree can look patchy even when the gene is present.
Penetrance (the probability that a carrier actually develops cancer over a lifetime) differs sharply by gene. MLH1 and MSH2 carriers face the steepest curves, MSH6 and PMS2 carriers usually develop cancer later and less often, and EPCAM deletions behave like MSH2. That single fact explains why one family with Lynch might see colon cancer at 35 while another sees endometrial cancer at 60, even though they share the same syndrome.
The older name hereditary nonpolyposis colorectal cancer (HNPCC) survives mainly in clinical criteria such as the Amsterdam standards and Bethesda guidelines, which doctors still use to flag families for tumor testing. Today “Lynch syndrome” is the preferred term because it captures the full spectrum of cancers, not just the bowel.
Tip: A diagnosis of HNPCC and a positive Lynch genetic test usually describe the same condition, but HNPCC criteria are clinical while Lynch syndrome requires confirmed germline mutation.
Colorectal and Endometrial Cancer as the Defining Lynch Malignancies
Colorectal cancer is the single most frequent Lynch-associated tumor. It often appears before age 50, arises in the right (proximal) colon where sporadic polyps are uncommon, and tends to be poorly differentiated with mucinous or signet-ring features under the microscope. Endometrial cancer runs a close second and is the most common extracolonic malignancy in women, frequently the sentinel event that triggers a family’s first genetic workup.
Lifetime Risk by Gene
| Gene | Colorectal Cancer Lifetime Risk | Endometrial Cancer Lifetime Risk (Women) |
|---|---|---|
| MLH1 | ~50–80% | ~40–60% |
| MSH2 | ~50–80% | ~40–60% |
| MSH6 | ~25–40% | ~40–70% (later onset) |
| PMS2 | ~10–20% | ~15–25% |
| EPCAM | ~50–75% (MSH2-like) | ~40–60% |
Both tumors share a molecular signature: microsatellite instability (MSI-H), meaning stretches of repetitive DNA show variable lengths in tumor cells because the MMR system failed to correct slippage errors during replication. Loss of MMR protein staining on immunohistochemistry (IHC), a lab technique that uses antibodies to detect specific proteins in tissue, points toward the gene most likely mutated. MSI-H plus absent MLH1 staining, for example, usually prompts a follow-up test for MLH1 promoter methylation (a chemical tag that silences a gene) to rule out a sporadic epigenetic event before germline testing is ordered.
In a 45-year-old woman with sudden, unexpected endometrial cancer, that tumor signature is often the first clue. In a 38-year-old man with a proximal colon tumor, it is the same clue, just in a different organ. Both stories lead to the same genetic counseling referral.
Yet those are not the only organs where Lynch leaves its mark, and several others carry risk that warrants equal attention.
Ovarian, Gastric, Small Bowel, and Urothelial Cancers
Four extracolonic tumors round out the elevated-risk profile beyond the colorectal-endometrial core: the ovaries, stomach, small bowel, and upper urinary tract lining. Each has a distinct pattern, and gene-specific counseling changes which one deserves the most attention.
Ovarian Cancer
Clear cell and endometrioid histologies dominate the ovarian tumors seen in this syndrome, contrasting sharply with the high-grade serous pattern that rules sporadic cases. Lifetime risk sits around 8–12% for MLH1 and MSH2 carriers and lower for MSH6 and PMS2, still well above the roughly 1.3% baseline risk for women in the general U.S. population. Onset tends to be earlier than sporadic ovarian cancer, often in the late 30s to 40s.
Gastric Cancer
Stomach cancer lifetime risk in Lynch carriers runs roughly 5–13% overall but climbs sharply in carriers who also live in high-incidence regions such as East Asia or parts of Central and South America, where H. pylori infection and dietary factors stack on top of genetic risk. Diffuse and intestinal histological types both occur, and tumors often appear in the proximal stomach (closer to the esophagus), an unusual location compared with sporadic gastric cancer.
Small Bowel Adenocarcinoma
A relative risk near 100-fold makes the duodenum and jejunum the most lopsided site of all, even though fewer than 1–2% of carriers will ever develop small bowel adenocarcinoma in their lifetime. The duodenum is the most common site. Because small bowel adenocarcinoma is so rare overall, any new case in a relatively young person deserves a Lynch workup regardless of family history.
Urothelial Carcinoma
Upper urinary tract cancers (renal pelvis and ureter) are over-represented in MSH2 carriers in particular, with lifetime risk estimates around 4–7% for MSH2 and lower for other genes. Blood in the urine without infection is the classic warning sign and should prompt a urology referral in any known carrier.
| Cancer | Approximate Lifetime Risk (MLH1/MSH2) | Key Clinical Clue |
|---|---|---|
| Ovarian | ~8–12% | Clear cell or endometrioid histology, age <50 |
| Gastric | ~5–13% (higher in endemic regions) | Proximal stomach, family history of gastric cancer |
| Small bowel | <1–2% absolute, ~100× relative | Duodenal tumor, young patient |
| Upper tract urothelial | ~4–7% (highest in MSH2) | Painless hematuria, MSH2 carrier |
Brain, Pancreatic, Prostate, Sebaceous, and Other Recognized Tumors
Several rarer cancers round out the Lynch tumor spectrum, each with its own demographic fingerprint and, in some cases, a named syndrome variant.
Brain Tumors and Turcot Syndrome
Gliomas, particularly glioblastoma, define the Turcot syndrome variant and frequently emerge during childhood or young adulthood, decades ahead of typical sporadic onset. Lifetime brain tumor risk in carriers is small, around 1–3%, but the age shift makes any new neurological symptom in a young carrier worth imaging quickly.
Sebaceous Tumors and Muir-Torre Syndrome
Sebaceous carcinomas of the skin and keratoacanthomas signal the Muir-Torre variant, in which MSH2 mutations account for the majority of cases. These lesions look like small, yellowish bumps on the eyelid or face and can appear years before any internal Lynch cancer, making them an early warning dermatologists sometimes catch first.
Pancreatic and Hepatobiliary Cancers
Pancreatic adenocarcinoma carries a lifetime risk around 4% in MLH1 and MSH2 carriers, with earlier onset than sporadic cases. Bile duct and gallbladder cancers are also over-represented, though absolute numbers remain modest.
Prostate Cancer
MSH2 and MSH6 carriers face a measurably higher prostate cancer risk than the baseline population, with tumors that more often display MSI-H features and behave more aggressively. Current NCCN guidance suggests carriers consider beginning shared decision-making about prostate screening in their 40s rather than waiting until 50 or 55.
Other Rare Associations
Adrenal cortical tumors, certain thyroid cancers, and sarcomas occasionally appear in Lynch families, enough to be listed in surveillance guidelines but too rare to drive population-level risk numbers. If a Lynch carrier develops any of these, it sharpens the case for keeping a tight relationship with a genetics-informed oncology team.
Expert insight: When two unusual tumors show up in the same family, like sebaceous carcinoma plus colon cancer, or glioblastoma plus endometrial cancer, think Lynch first and reach for germline confirmation before assuming two unrelated sporadic events.
How Tumor Testing Leads to a Lynch Diagnosis
The diagnostic path almost always starts in the tumor itself, not in the blood. Two cheap, fast assays on the original cancer specimen decide whether germline testing is worth pursuing.
Tumor Screening: MSI and IHC
Microsatellite instability testing (usually a PCR-based panel of five markers) classifies a tumor as MSI-H, microsatellite stable, or low. IHC stains for the four MMR proteins and shows which one is missing inside the tumor cell nuclei. MSI-H plus loss of MSH2 and MSH6 staining, for example, points strongly toward an MSH2 germline mutation. MLH1 loss, however, can be sporadic (driven by somatic MLH1 promoter methylation), so a follow-up methylation test or BRAF V600E mutation check is performed before germline sequencing.
Germline Confirmation
A blood or saliva sample sent to a clinical lab sequences MLH1, MSH2, MSH6, PMS2, and EPCAM. Multigene panels often add other hereditary cancer genes (APC, MUTYH, TP53, BRCA1/2) so the lab can distinguish Lynch from familial adenomatous polyposis (FAP), Li-Fraumeni syndrome, or hereditary breast and ovarian cancer syndromes that sometimes overlap in family history.
Variant Interpretation and Cascade Testing
Not every sequence change is dangerous. Labs classify variants as pathogenic, likely pathogenic, of uncertain significance (VUS), likely benign, or benign. A VUS cannot be used to guide screening or to test relatives. Genetic counselors walk families through what each result means and, for clearly pathogenic findings, organize cascade testing: offering the same genetic test to first-degree relatives so each person can learn their own carrier status.
Warning: Sharing a VUS result with relatives as if it were a positive finding causes needless anxiety and screening. Wait for a genetic counselor to clarify whether the variant actually changes anyone’s care.
Insurance and Privacy Protections
The Genetic Information Nondiscrimination Act (GINA) bars health insurers and employers from using genetic information against you in most U.S. settings, though life, disability, and long-term care insurance are not fully covered. Knowing this in advance helps families talk through results without delaying out of fear.
Because a confirmed tumor result then sets practical expectations, it shapes the surveillance roadmap families will follow for years.
Screening Roadmaps and Next Steps for Carriers and At-Risk Relatives
Once a pathogenic variant is confirmed, the goal shifts from diagnosis to early detection. The National Comprehensive Cancer Network (NCCN) updates its Lynch syndrome guidelines regularly, and most specialists anchor surveillance to the specific gene involved.
Colon Surveillance
- Colonoscopy every 1–2 years: Starting at age 20–25 for MLH1 and MSH2 carriers, age 25–30 for MSH6 and PMS2, or 2–5 years before the earliest family diagnosis, whichever comes first.
- High-quality prep and chromoendoscopy: Subtle flat polyps are common, so full bowel prep and, where available, dye-spray endoscopy improve detection.
- Consider risk-reducing surgery: Subtotal colectomy (surgical removal of most of the colon) is a discussion point after a Lynch colon cancer, since metachronous tumors (new, separate cancers developing later) are common.
Endometrial and Ovarian Surveillance
- Annual endometrial sampling or ultrasound: Starting around age 30–35, though sensitivity for early cancer is imperfect.
- Discuss risk-reducing hysterectomy with BSO: Removal of the uterus, fallopian tubes, and ovaries (bilateral salpingo-oophorectomy, or BSO) is the most reliable option once childbearing is complete, especially for MLH1 and MSH2 carriers.
- Prompt evaluation of abnormal bleeding: Any new bleeding pattern deserves a same-week gynecologic visit.
Upper GI, Urinary Tract, and Other Surveillance
- Upper endoscopy every 2–4 years: Especially for carriers with a family history of gastric cancer or for those living in high-incidence regions; H. pylori testing and treatment are part of the routine.
- Annual urinalysis: Aimed at detecting hidden blood, a flag for upper tract urothelial cancer, particularly in MSH2 carriers.
- Consider pancreatic surveillance: MRI or endoscopic ultrasound (EUS) starting around age 50 for MLH1 and MSH2 carriers with a family history of pancreatic cancer, per NCCN.
- Skin exams: Annual dermatology visits catch sebaceous neoplasms early in MSH2 families.
Family Communication and Cascade Testing
Tell first-degree relatives (parents, siblings, children) as soon as a pathogenic variant is confirmed. Each has a 50% chance of carrying it, and their own screening plan depends on knowing. Genetic counselors can supply a family letter template, review the medical details, and help navigate awkward conversations without pressure.
Reassessing the Plan Yearly
Genetics care is not a one-time event. New evidence, evolving NCCN guidelines, and personal health changes mean the plan should be revisited with a genetics-informed clinician at least once a year, and sooner if a new cancer diagnosis appears in the family.
The Big Picture
Lynch syndrome touches nearly a dozen organ systems, but its weight is concentrated: colorectal and endometrial cancers together account for the majority of cases, with ovarian, gastric, small bowel, and urothelial cancers forming a meaningful second tier. Knowing your specific gene turns that long list into a personalized screening calendar, and tumor testing followed by germline confirmation is the most reliable path to that knowledge. If Lynch runs in your family, the next step is a conversation with a genetic counselor who can turn the science above into a concrete plan for you.
FAQ
Which cancers are most commonly linked to Lynch syndrome?
Colorectal and endometrial cancers are the two defining Lynch malignancies, together making up the majority of cases. Ovarian, gastric, small bowel, and upper urinary tract cancers form the next tier of risk, while brain, pancreatic, prostate, and sebaceous skin tumors occur less often but still more frequently than in the general population.
Does Lynch syndrome increase the risk of cancers other than colon?
Yes. Lynch raises risk across several organs, with endometrial cancer being the most common extracolonic tumor in women and ovarian, gastric, small bowel, urothelial, brain, pancreatic, prostate, and sebaceous skin cancers all recognized as part of the syndrome.
How high is the lifetime cancer risk for someone with Lynch syndrome?
Lifetime colorectal cancer risk ranges from roughly 10–20% in PMS2 carriers up to 50–80% in MLH1 and MSH2 carriers, while endometrial cancer risk in women runs from about 15% (PMS2) to 40–70% (MSH6, with later onset), underscoring why gene-specific guidance matters.
Are ovarian and stomach cancers part of Lynch syndrome?
Both are recognized Lynch-associated cancers. Ovarian lifetime risk sits around 8–12% in MLH1 and MSH2 carriers with non-serous histologies over-represented, and gastric cancer lifetime risk runs about 5–13% overall, climbing in carriers living in high-incidence regions.
How often should someone with Lynch syndrome be screened for cancer?
Colonoscopy every 1–2 years starting at age 20–25 (MLH1/MSH2) or 25–30 (MSH6/PMS2), annual endometrial sampling or ultrasound for women from the mid-30s, upper endoscopy every 2–4 years, annual urinalysis, and skin exams are typical components, with pancreatic imaging added for higher-risk families.
Can Lynch syndrome skip generations?
Autosomal dominant inheritance means the mutation itself does not skip generations, though an unaffected parent who does not transmit it can make the family tree appear to skip. That is why each first-degree relative needs their own genetic test rather than relying on the parents’ results.
